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ObHws. ‘l&s dose-response study was designed to test two 
low dose rogimms of areklnase administered uver a prolunged 
time pedod in patieuts with chroak refractory aagloa pectorls 
witb mpect to e&cts 00 clinkal symptoms aad objective vari- 
abks ufmyocard&l iscbeiuii 
lladgmd Patknts wltb severe and chramk refractory aa- 
glue pectork in end-stage corowy artery disease represent an 
increasing cliokal ptwbkm. Favarable tbcrapwtk e&cts oa 
myaeardlal kchemia have been reported for bng-tenn si~-8lkation 
of low dose orokiwse. 
Metboth. Ninety-cl@ patients with cbrunk refwtury tmd 
end-stagecorouarytierydiseasewmrandomlyass@cdtotwo 
treatment groupsz gtwop A (49 patients) receiwd Stl,tl@ll IU aad 
gruup B (49 patients) seb,@tlO IU uf umklnase as aa iatravem 
bolusiqieetioatbreetilsesawedrmeraporiodot12~ 
Vtuiables evalaPted were number of weekly angloal CveitncS, data 
from ergometric exercise testing wlth simultatwus ekctrucaniii 
Therapeutic options for the management of angina pectoris in 
patients with coronary artery disease have increased and 
improved impressively over the past 25 years. Next to ?be three 
mainstays of medical therapy (nitrates, beta-adrenergk block- 
ing agents and calcium antagonists). invasive procedures such 
as coronary artery bypass graft surgery and percutaneous 
transluminal coronary balloon angioplasty have been estab- 
lished as effective means of reducing myocardial &hernia and 
hence angina1 symptoms. Still, clinicians can identify patients 
with severe symptomatic coronary artery disease who are 
refractory to conventional medical as well as to invasive 
therapeutic approaches. Because sun+1 of patients with 
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graphic registration, .:emiquantitative cvaluatian of Tc-99m 2- 
metboxy isobutyi isoaitik (MIBI) scans sod rbe&jc vsrhbks. 
Red&. After It we&s of treatment, aaginal symptums (events/ 
week) were reduced signilkantly in gruup B by 70% compared wltb 
24% in group A (p < @.ftOl). Fibrioogen d===fby=iBgrollP 
Aradby3J%io~pB(p<Q.801).Plrs~visrosityoadIpd 
blood cell slggmgatioo were redoccd by 6.4% (p < e.aw and 
19.9% (p < O.@tJl,, respectively, in gruup B. O&-tiw wiables of 
lgtocPrdblisebeDdrWUViolpwcdsij@BUatlyin@UEpBOIdy.Nn 
cltmulatlonofLwoDplrkcltemkeventswsobsavedktgcnopR 
m. Long+rm iatermitteat oroldnase therapy in aa 
applleddaseof3xXKt,~lU/weekreprwotsaaefective 
aati-iscbcmk and antiaaginal appruad8 for patknts ti t+ac- 
toryaegiaapectorisandend-stagecumaary~dlsease.Apart 
from rhwlogk impmvemen~ autlthrumbotk prupcrtks and 
plaque regrrssioa are likely anti-lscbemk mechanisms. 
(J Am Cdl Gvdiol199&27:575-84) 
coronary artery disease is increasing as a result of improved 
secondary prevention, ar. increase in the prevalence of patients 
with refractory angina pectoris is to be expected. 
For patients with refractory angina pectoris, long-term 
intermittent urokinase therapy as a combined rheologk and 
thrombolytic approach to the improvement of myocardial 
perfusion was developed (1.2). The first observational studies 
in patients with refractory angina pectoris (3.4). which evalu- 
ated the effect of 3 X 5tWOO IU urokinasetieek over a period 
of 12 weeks, demonstrated a significant amelioration of anginal 
symptoms and objective signs of myocardial ischemia accom- 
panied by a significant reduction in fibrinogen levels. 
To further investigate the validity of these observations, a 
dose-response study was designed that compared the intrave- 
nous administration of 3 X 50,000 1U of urokinase with a 
dosage of 3 x XWOO IU urokinaAweek over a period of 12 
weeks. The objective was to demonstrate whether there is a 
dose-dependent influence of long-term intermittent urokinase 
therapy in patients with retioty angina pectork regarding 1) 
clinical symptoms of 111. -. fial isehemia, 2) objective vati- 
ables of myocardial is&en.., and 3) safety of this form of 
therapy. 
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Methods 
Study design. The study was designed as a single-blind trial 
in which patients had no knowledge of the dosage and were 
randomly assigned to one of two treatment groups. In both 
groups, urokinase (Urokinase Medac) was administered intra- 
venously as a bolus injection three times a week over a period 
of 12 weeks (36 injections). Patients in group A received .5O.GI 
Ill/injection, and those in group B received 5OO.ooO IU/ 
injection. 
During the outpatient treatment period, laboratory vari- 
ables as well as diaries for evaluation of angina1 symptoms 
were checked every 2 weeks; conventional medication included 
low dose aspirin (!OO mgiday) in all patients and was continued 
as prescribed at the beginning of the trial. Ergometric exercise 
testing and myocardial stress scintigraphy were performed 
before and after the treatment period. 
To guarantee maximal safety for patients undergoing a 
long-term therapy with a thrombolytic agent, and in accor- 
dance with the standards set for this study by the ethics 
committee of the medical faculty of the Heinrich-Hcine Uni- 
versity, injections of urokinase and primary evaluation of 
angina diaries and laboratory variables were carried out in a 
single-blinded manner. Final evaluation as presented in this 
report was double-blind for angina diaries; laboratory vari- 
ables; and two independent studies of exercise testing, includ- 
ing ST segment analysis and myocardial stress scintigraphy. 
All patients were enrolled in the study with the approval of 
the prima:y care physician. and all patients gave written 
informed consent. The study was approved by the ethics 
committee of the Heinrich-Heine University. 
Patients. The study included 98 patients with severe angina 
pectoris (Canadian Cardiovascular Society angina class III or 
IV IS]) de+ite the maximal antianginal therapy (beta-blockers 
nitrates and calcium antagonists) that did not produce relevant 
side effects. Patients with chronic intermittent episodes of 
chest pain at rest were also classified as eligible If they did not 
have newly developed rest pain within the preceding month or 
other forms of unstable angina pectoris (6). The option for an 
invasive revascularization procedure had been ruled out before 
entry into the study by an experienced team of cardiologists 
and cardiac surgeons after review of a coronary angiogram that 
had been assessed within 3 months before entry into the study. 
The major reason for exclusior! firm rivascularization proce- 
dures was unsuitable coronary anatomy for mechanical inter- 
ventions, such as dilfuse coronary atherosclerosis which ex- 
tended to the periphery of the epicardial conductance vessels. 
Further criteria for exclusion were repeated unsuccessful in- 
terventions in the culprit lesion for reduction of myocardial 
ischemia, lack of graft material and a high peri-interventional 
risk due to severe left ventricular dysfunctkm in some patients. 
Because the study was directed toward evaluation of the 
rheologic impact of long-term intermittent urok&se therapy, 
patients with fibrinogen levels >250 mg/dl W+ZR selected to 
increase the chance of detecting a relation behveen clinical 
benefit and improvement of blood rheohqic variables. 
Throughout the trial. conventional antianginal medication as 
well as l(W) mg aspirin/day WPS continued in each patient. 
Patients were not included in the trial if they met one or 
more of the following criteria: myocardial infarction within the 
preceding 6 months, severe heart failure (New York Heart 
Association functional class IV), hemodynamically significant 
valvular heart disease, hypotension (systolic blood pressure 
< to0 mm Hg) or hypertension (systolic and diastolic blood 
pressures >I60 and ~90 mm Hg, respectively), clinical evi- 
dence of intermittent tachyarrhythmia. evidence of chronic 
inflammatory disease or other relevant organ dysfunctions or 
contraindications for anticoagulation. 
Patients were excluded from final evaluation if they devel- 
oped one of the following conditions during the course of 
treatment: subjective discomfort. gastrointestinal bleeding, rc- 
duction of fibrinogen levels < I50 mg/dl, myocardial infarction 
or death. Patients with an increase of angina1 events by ~56% 
during two successive weeks were excluded from further 
treatment for possible adverse reactions. These patients were 
again admitted for in-hospital monitoring for unstable angina 
pectoris and treated accordingly. Screening procedures for 
bleeding complications (serial blood count. stool guaic test, 
endoscopy) were performed according to clinical judgment 
with a high index of suspicion. Patients with evidence of 
bleeding complications were excluded from further treatment. 
Under these preconditions, the final evaluation included 43 
patients in group A acd 46 patients in group B. 
Evaluation of spontaneous anginaI symptoms. Patients 
recorded the number of angina1 episodes as well as the intake 
of the number of fast-release nitrate capsules daily in a diary. 
As for the known placebo effect of -40% in antiangina] studies 
(7.Q positive responders were classified as patients who had 
relief of symptoms during the final 2 weeks of the trial by 
~66% compared with the initial number of weekly anginat 
episodes. 
Ergo&& exe&e testing and ST segment dysis. Two 
independent exercise texts (bicycle ergometry) that included 
electrocardiographic registration (leads I, II. Ill, V, V.,, V,), 
were performed before and after 12 weeks of treatment. 
Patients who received digitalis, demonstrated left bundle 
branch block or atrial fibrillation or who had a cardiac pace- 
maker were excluded from evaluation of ST segment changes. 
End points for exercise testing were chest pain. exhaustion or 
ST segment depression ~0.3 mV. 
&mciw s&y I. Exercise was performed in the sitting 
position and started with 25 W, work load was increased every 
I20 s by 25 W. Patients exercised until they reached one of the 
end points before and after treatment. Variables evaluated in 
all patients were I) end point at termination of exercise 2) 
exercise capacity as expressed by cumulative work performed 
(J), 3) maximal heart rate (beats/min) and nte-prc~re 
product(MaximaItlealtntexMaximat~hbaIprer- 
sure x 0.01). and 4) average ST segment depn+on (mv). 
Patients who demonstrated angina pectoris and ST segment 
depression~.lmVOIlbOth occssionslwereevaluatedfOl5) 
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ANTERIOR 
l@me 1. Technetium49m MIBI SPECT 
polar map of Patient 23 in group B. 
The center of the diagram shows the 
apex region, and the other segments 
are arranged around the center up !o 
the base of the heart. Before jrcat- 
merit the global stress index (c) as 
derived from relative activity at rest (a) 
with respect to relative activity after 
exercise fb) amounted to a cumulative 
value of 384. After treatment (d), dhe 
stress index had improved to 2.38. 
POSTERIOR 
time to angina1 symptoms (s) or 6) time to negative ST segment 
depression of 0. I mV (5). or both. 
Ererrke 57~4 If. Before treatment. patients in exercise 
study Ii exercised in the supine position until one of the end 
points was reached. Patients started with 25 W. and work toad 
was increased every 60 s by 25 W. Because exercise testing in 
this ca.. was part of ergometric stress scintigraphy. patients 
exercised to the same level of work toad (W x s) after the 
treatment period to reproduce a comparable level of myocar- 
dial stress. Variables evaluated in all patients were I) reason 
for termination of exercise (end point). 2) exercise capacity as 
expressed by cumulative W x s performed (J). 3) maximal 
heart rate (beats/min) and rate-pressure product (Maximal 
heart rate x Maximal systolic blood pressure x 0.01). and 4) 
average negative ST segment depression (mV). Patients who 
demonstrated angina pectoris and ST segment deprwion 
X1 mV on both oazions were evaluated for 5) time to 
anginaf symptoms (s) or 6) time to negative ST segment 
deprehn of 0.1 mV (s), or both. 
Mpad&l m. Scintigaphic itnags ume ac- 
quired aBer injection of 550 to 770 MBq of Tc-99m 2-methoxy 
iso&@lkta&le(MlBI)atrestandafterergometricex&se 
1esling(aoEordinl(10theprntoodof elmrise study II) on two 
successive days. Technetium-99m MlBi was chosen because it 
almost exclusively repteseniz myocardial perfusion (9) and for 
reasons of image quality. Images wzre acquired with a .M# 
rotating single-head camera in single-photon emission corn- 
puted tomographic (SPECT) technique 2 h after injection. 
Relative percent uptake of Tc99m MIBI in relation to maxi- 
mal uptake was presented in the form of a polar map derived 
from the short-axis view (IO.1 I) (Fig. I). Because the SPECT 
technique does not provide absolute values for myocardial 
pufusim petcent chnges in the stress and rest polar maps 
werecombinedasastressindexandsbovnonaneupolarmap 
(IZ).Theabsoluteslmdallperantdrangespovideda~ 
stress in&r Positive indexes represent a relative increase. and 
negative indexes mark a decre3sl in relative perfusinn. In 
nomlalsubjeasthcpcnxntchangcssltaddbeclosetnzefu 
because there is no change in relative uistribution of petfu&m 
at resa and atier exerti tearing Therefore. in patients with 
cmmty army disea, all chanfl reflect redistriiuon of 
perfusiooasasig!lof~rdial~ 
lahmrynrykrBbodsaJnpksweledtawnbefore 
entsyintothestudyandevety2weeksduringthetrwtment 
periodbeNeul88nd10AM.t%smafih&+rwasmasured 
byamodificdmcdml~to~~(l3)ia9cldoCwhok 
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Table I. Patient Characlcristics 
Cirm~p A 
(II -= ‘IV) 
Group B 
(II - W) 
Group A n. All Patients 
Group B (II - VU) 
Age (yr) 
Malt (‘i) 
Myrwardial infarction (‘c) 
CABG (‘i) 
Time since CAffi (mo) 
Angina clas IV (‘;) 
Frequency of angina pectoris (evcntsbvk) 
lntakc of nitraw capsules (capsules wk) 
Mcdicafion 
Nitrates ((i) 
Beta-hltrkcn (‘i) 
Calcium antagonia (? ) 
Triple combination thcrap (‘t ) 
Rheokqic variahlc, 
Fihrinogcn (mg’dl) 
Plasma vivxsily (mPa) 
Red hltwd ccl1 agrcgrtion (U ) 
Data from invasive prwcdurcs 
Coronary rripic-vcwl di\casc (%) 
CABG 
Retrclusion 
Left vcntriiular ejection fraction (C;) 
Lcfi ventriilar end-diastolic prcsorc (mm Hg) 
61 *‘I 63 ? 0 
V1 Yll 
353 2 7’) 
I3 5 lI.llY 
l-I.9 c 3.0 
1Oll 
3.2 2 I.0 
1.6 2 1.0 
46z I8 
17.7 2 6.X 
x2 
71 
7x + 13 
63 
%I 2 I I.6 
14.1 f I I 
l l l l l 
711 
VX 
67 
364’6i 
I.39 -t O.(h 
I-l.6 t 2.x 
YX 
3.J ? I.(1 
I.i + I.? 
Jnz I7 
17.4 ? 4.‘) 
lW5 XY 
wm 70 
(I.343 76 2 J.? 
0.110 ?+I 
0.613 23.’ + I0.X 
0.7Y3 13.v f V.6 
I II)0 
lJ.65S 71 
0.168 95 
I 67 
li.3Y7 35’) f 73 
ll.3Y6 1.3’) z O.ll7 
IJ.XVI Id.7 2 ?.Y 
0.3 IO YY 
0.370 3.3 + I.0 
0.6lUxI) I.6 2 I.0 
O.Mul 47% I7 
O.lUNl 17.7 _C 6.7 
Dala presented are mean 2 SD or gcrccnt of patients. CABG = cortrnary ancry bypass graft surge?. 
blood added to 1 ml of sodium citrcte (Multifibren. Behring- 
werke). Fibrinogen levels were shown to be 227 ? 50 mg/dl 
(mean -C SD) (n = 16) in healthy subjects and to 295 t 
69 mgldl (n = 44) in patients with coronary artery disease and 
stable angina pectoris (14). 
Plasma viscosity was measured in venous blood anticoagu- 
lated with EDTA at 37°C in a capillary tube viscosimetel 
(KSPV 4. Rheomed). In healthy subjects a mean value of 
1.24 -C 0.07 mPa X s (n = -34) was found. but in patients with 
coronary artery disease and nonrefractov an&ma pectoris. a 
mean value of 1.33 ? 0.08 mPa X s (n = 78) (14) was reported. 
Red blood cell aggregation was analyzed at instananeous 
hematocrit with the aggregometer MA-I (Aggregometer, 
Myrenne GmbH), which uses the light transmission meihod 
according to Schmid-Schoenbein et al. (15) at zero shear rate. 
The mean value was fol;nd to be 9.6 t 3.2 U in healthy subjects 
(n = 28) and 13.1 -C 3.1 U (n = 42) in patients with coronary 
artery disease and nonrefractory angina pectoris (14). 
Statistics. The data were analyzed with the statistical soft- 
ware SPSS 6.0. Baseline characteristics of the study groups 
were tested for significant differences with the Student r test for 
unpaired observations and the chi-square test. The time course 
of dependent variables was tested for intergroup differences 
with a two-way repeated-measures analysis of variance model. 
Where needed, correlation coefficients were generated with 
the Pearson bivariate correlation test. 
Results 
Patients. Of the 98 patients admitted to the study 70%, 
had undergone coronary artery bypass (Table 1). Almost all 
patients suffered from coronary triple disease; about 50% of 
the bypass vessels implanted were occluded. In addition to 
severe coronary insufficiency, relatively large amounts of 
viable myocardium could be assumed as reflected by an only 
moderately impaired left ventricular function at rest. Pa- 
tients demonstrated pathologic elevations of rheologic 
blood properties, as fibrinogen levels and dependent rheo- 
logic parameters were elevated not only in respect to normal 
controls but also in comparison to patients with coronary 
artery disease and nonrefractory angina pcctoris (14). Two- 
thirds of the patients had angina class IV; only 60% 
tolerated antianginal triple combination therapy. Both 
groups were comparable in respect to baseline parameters 
except for a higher incidence of myocardial infarction in the 
history of patients in group B. 
Laboretoq variables. Only group B demonstrated a signif- 
icant decrease of fibrinogen levels with reductions by an 
average of 33% at the end of the study compared with 3% in 
group A (Table 2); these were accompanied by reductions of 
plasma viscosity (-05% in group A; -6.4% in group B) and 
red blood cell aggregation (-5.1% in group A; -19.% in 
group B). As expected, there was a highly positive correlation 
between fibrinogen and plasma viscosity (r = 0.78, p < 0.001) 
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Table 2. Rheologic Vlriahles Beforr and After Trevrmcnt 
3 x .SU.lllk~ IU UKWcck 3 * jrll.tllNl IU UKWeck 
(II - 431 (n = 46) 
More .4kr Bcforc AfWl 
(mean z SD) (mean I SD) (mean f SD) (mean I SD) p Value 
Fibrinogen (mgdl) 351 - n 333 2 h3 wtlh ‘42 z JO c n.lnll 
Plasma viscosity (mPa) 13 f 0.09 1.37 1 IWY I.40 f Il.05 1.31 z 0.0s ( 11.11ll 
Red bawd cell aggregation (U) IS.11 ? 3.0 14.0 2 3.2 14.x z 2.7 11.7 + 23 OWI 
UK y urokinase. 
and red blood cell aggregation (r = 0.60. p < 0.001) over the 
whole group. 
Aogioal symptoms. Reductions of angina1 symptoms 
(events/week) were associated with changes of rheologic vari- 
ables in their time course (Fig. 2). with a reduction of 25% in 
group A and 70% in group B (Table 3). When the two groups 
were compared according to responders, 2:s of the patients 
demonstrated a decrease in angina1 events/week of more than 
Fit 2. Time course of clinical symptoms and fibrinogen during 
treatment three times a week for 12 weeks with 5fJ,OOO IU urokinasel 
injection (opeo eirtks, group A) or 500,ooO IU urokinase/injection 
(ebsed eir&s. group B). Changes in group B during treatment 
differed significantly from group A for both variables (p < fMNll). 
Oi 1 8 
0 2 4 6 6 IO 12 
week ol lrealmml 
66% in group A, but this was true for 70% in group B. At the 
end of the treatment period. 7% were completely asymptom- 
atic in group A compared with 17% in group B. 
Epmctrk cxereise testing rad ST segment anatysk 15 
erciw sfud~ 1. Although there was no significant change in 
group A (Table 4). exercise capacity increased markedly by 
60% in group B. In group B, a significant reduction in patients 
who “stopped for angina pectoris” which represented a shift of 
end points from “stopped for angina pectoris” to “stopped for 
exhaustion,” could be demonstrated. Averaged ST segment 
depression decreased signiticantly only in group B in addition 
to an increase in “time to angina pectoris” and “time to 
negative ST segment depression >O.l mV.” 
Premise sr~dy II. Roth groups showed no signiticant differ- 
ences of maximal heart rate and rate-pressure product (Table 
4) before and after treatment indicating a comparable level of 
myocardial stress. Results reflected those from exercise study I 
insofar as significantly fewer patients stopped exercise with 
angina pectoris in group B. Average ST segment depression at 
the end of exercise was significantly reduced in group B after 
the treatment period. as was time to ST segment depression of 
0.1 mV. 
Myocadal seimtigmpby. Myocardial stress as expressed 
by the results from exercise study II (Table 4) was comparable 
before and after treatment in both groups. After treatment the 
scintigrapbic stress index as a variable of myocardial pemsion 
was significantly reduced toward zero in group B (from 269 ? 
95 to 231 2 84. p < 0.014) as compared to the timely change 
in group A (from 249 2 76 to 258 ? 91) (Fig. 3). 
!Me e&ts. In five patients in group A and two patients in 
group B, treatment had to be stopped for an increase ofclinical 
symptoms by ~56%. indicating unstable angina pectoris or 
myocardial infarction (Table 5). Of these. two patients in 
group A and one patient in group B had a myocanM 
infarction as documented by electrocardiographic alterations 
as well as by significant elevations of creature kinase activity; 
no patient died in the course of the treatment. One patient in 
groupAquitfurtbertreatmentforwspeci8creasons andwas 
atso excluded from final evaluation. 
Nopatientshowedadecreaseoftibrinogenlevek<l~0 
dloramarkedincrease in activated partial thranbopltstin 
time indicating an elevated risk for bleeding complications. 
Nevertheless. one patient in group B developed an upper 
gastromtestinal bleeding complication in the secard week of 
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Table 3. Subjective Vari,.hles of Mytrardial Ir;chemia Bcforc and After Tre:!!mcnt 
3 < 5ll.lnrl IL; UK,Wcck ,I r: slill.lnnl IU UI(‘Wsch 
(n 43) (II = Jh) 
__- -__ 
ndorc A(1cr Bcforc Alicr 
Anfins pcclorl* (cvenls.wk) 2l.U ! 0.x 1s.s ! 1ll.11 24.2 ? Il.7 7.1 f 7.1 
lnlskc of nitralc cap\uiL\ 13.1 ? 7.9 R.Y t 6 I 14.1 ’ 11.1 2.3 : 3.4 
(capukdwh) 
Rcspondcn (reduction of angina !I 71) 
ptxlori\ ; Wi) (5) 
Pt, free of 5Frnptomb (5 I 7 I7 
Dara prcsenred arc mean value +_ SD or pcrcsnt of patients (PI%). UK = urokinasc. 
treatment, which could be attributed to duodenal ulceration. 
The cardinal symptom was tarry stool, and hcmoglocin was 
reduced to a minimum of I I .2 g/d1 (IS.6 g/d1 before treat- 
ment); hemostatic variables were measured in the normal 
range (fibrinogen 240 mg/dl. activalzd partial thromboplastin 
time 30 s). Even though no clear evidence for a prior history of 
gastroduodenal ulcers could be establislvd. it seems probable 
that treatment with aspirin may have had a triggering effect on 
latent ulcer disease in this patient. In 24 patients in group A 
and in 27 patients in group B. blood counts were assessed at 
the ber.,:xing of the study and within the last 4 weeks of 
treatment. No significant differences could be documented 
hetween time points or between groups in respect to red blood 
cell count, hematocrit. platelets or white blood cells. 
Discussion 
Anti-ischemic effectiveness of long-tenn intermittent uroki- 
nase therapy. This study provides strong evidence for a dose- 
dependent favorable effect of long-tcrrn intermittent urokinase 
therapy on myocardial ischemia and angina pectoris in patients 
with refractory angina pectoris in end-stage coronary artery 
disease. A therapeutic regimen of 3 X SOO,O@O IU urokinasel 
week over d period of 12 weeks produced significant reductions 
of clinical symptoms after 2 to 4 weeks accompanied by 
significant improvements of variables of myocardial &hernia 
at the end of the study. Even though the low dose used in 
group A (3 X 50.000 IU urokinasefieek over a period of 12 
weeks) Icd to a significant decrease of angina1 attacks, this may 
Table 4. Objective Variables of Myocardial lschemia Before and After Treatment 
3 x 5O.llW IU UlW’cck 3 x .Wl.WI~ IU UK/Week 
No. of No. of 
l3eforc After PIS Bcforc After hb p vahlc* 
Exercir study I 
Max work load (J) 
Max HR (IxaWmin) 
Max RPP (mm Hg X heatsimin x 0.01) 
End poim 
Angina pecloris 
Exhaustion 
Negative ST segment deprcGm X1.3 mV 
Time IO ST segment dcprcssion 0 1 ~IV (s) 
Time IO angina pcctoris (s) 
Negative ST scgmcnl depression at max work load 
Exercise sludy :I 
Max HR (h~atsimin) 
Max RPP (mm Hg x heatslmin x 0.01) 
End poirx 
Angina ~~Woris 
Exhaustion 
Negative ST segment depression >I).3 mV 
Stopped for end of protocol 
Time to ST segment depression 0.1 mV (s) 
Negative ST segment depression al max work load 
3l.82 f I I.:,! 
II)1 + I7 
lbb”39 
.3b 
b 
I 
340x+ II7 
361 I II’) 
0.1s ? 0.13 
Wf IX 
15X 2 22 
33 
Ill 
0 
167 5 50 
0.13 z 0.11 
21.61 + I I.57 43 20.20 + 12.15 27.Y3 z I?.M 46 < O.M~l 
IO.3 2 IX 43 104 2 I9 1117 ? IX 46 n.cir) 
I76 C 4Y 43 lb0 z 43 I73 -t 43 46 0.2lfl 
35 32 I4 o.s2w< O.(Jl)l 
7 I3 32 Ih.nY/< IMIll 
I I II INwx 
3ln1 2 I I?. 29 xn~X9 371:8x 35 0.074 
.3fl3 2 115 
0.14 r 0.12 
29 
I? 
0 
2 
16X-cSl 
0.12 2 0.10 
3s 351 2 I31 
36 lb.15 ? 0.12 
43 loo? I9 101 2 I7 
43 15’) ? 43 Ih? % 42 
29 
I7 
0 
29 1MIr53 
36 0.14 -c 0.10 
439? I31 
0.1 I ? 0.09 
14 < O.OOl 
3X < O.oll I 
-lb 0.221 
44 0.117 
Wb3/1l.014 
0.284m.357 
- 
- 
35 0.001 
38 < 0.01 
‘Two-way repeated-measures anal@ of variance or chi-square test for frequencies (group A vs. group 5. before/after treatment). Data presented are mean value Z 
SD or number of patients (hs). HR = hean rate; max = maximal: RPP = rate-pressure product: UK = urokinasc. 
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Figure 3. Scintigraphic global stress index before and after treatment 
three times a week for I? weeks with (a) 50,CKM Ill urokinaselinjection 
and (b) 54lO.ooO IU urokinaselinjection. After treatment. the global 
stress index was significanriy reduced in the group that received 
SOO,ooO IU urokinase/injection (p = 0.014). 
have to be attributed lo a placebo effect, as reductions aver- 
aged 25%, which ranges within the limits of known placebo 
effects (7,8). The favorable changes of objective variables of 
stress-induced myocardial &hernia demonstrated in group B 
were not accompanied by significant decreases of determinants 
of myl,cardial oxygen demand such as heart rate and rate- 
pressure product. Therefore, the reduction of myocardial 
ischemia has to be attributed to an increase of oxygen supply 
and not to a peripheral training effect (16). 
Rhdogic mechanisms of anti-M ehctiieness. Be- 
cause the favorable therapeutic effects in group B were accom- 
panied by significant decreases of fibrinogen, it can be assumed 
that therapeutic effectiveness is in part mediated by the 
improvement of rheologic blood properties and subsequent 
increases in blood fluidity. In nonobstructed coronary arteries, 
the flow-limiting resistance caused by blood viscosity, which is 
mainly determined by plasma viscosity, red blood cell aggre- 
gation, red blood cell deformability and hematocrit, can be 
Tabte 5. Side Effects of Treatment 
3 x 50,mo 3 x mm 
IU UK/Week NJ UWVeek 
(n = 49) (n = 49) 
ulLslabk all&+3 pectorb 3 I 
Myocardial infarction 2 I 
Upper ptmintestinai bleeding 0 I 
Droppedoutforno5qec&reason I 0 
Data presented are numb of patienrr UK = umkinase. 
neglected (17,18). However. in the poststenotic microcircula- 
lion of severely stenotic or occluded vessels as well as in 
collal~ral vessels (IV). blood viscosity and especially plasma 
viscosity and red blood cell aggregation may become a flow- 
limiting factor and therefore be critical for oxygen delivery to 
the ischemic myocardium (20). At the extremely low shear 
rates with an almost zero flow in this area (21), macromole- 
cules, in particular fibrinogen, lead to an increased plasma 
viscosity and red blood cell aggregation (“roulleaux phenom- 
enon”), which in turn leads to an exponential increase in blood 
viscosity (17.18,22). Even though the reductions of rheologic 
variables in group B were low in respect to the improvement of 
symptoms, it has to be noted that minor changes of rheologic 
blood properties as measured in the macrocirculation at 
relatively high shear rates may reflect major changes at low 
shear rates in the coronary microcirculation (1518). 
Antitbrombotii mecbaoisms of anti-iscbemk effdveness. 
Apart from the acute coronary syndromes. plaque fissures or 
thrombi have been demonstrated in the coronary arteries of 
22% of patients with atheroma-related disease who died of 
noncardiac causes (23). Therefore, they may be of flow-limiting 
relevance in the epicardial conductance vessels (24) as well as 
in the coronary microcirculation (25.26) in clinically stable 
patien&s. With regard to evidence from epidemiologic trials 
and for pathogenetic considerations, elevations of fibrinogen 
levels themselves have to be regarded as promotors of intra- 
coronary thrombus formation (27-29). Multiple severe and 
often successive coronary stenoses. as demonstrated in the 
patients investigated. lead to regions of poststenotic recircula- 
tion and relative stasis of blood flow. These fluid dynamic 
aspeprs of coronary stenoses in conjunction with reductions of 
blown! fluidity from elevations of plasma viscosity and red blood 
cell aggregation favor intracoronary thrombus fomtion (30). 
Prodlrombogenic factors may also be of particula: rele- 
vance in venous graft material, which i, inferior to autologous 
mammary-coronary anastomosis because of a higher rate of 
graft closure (31$2). Even though coronary ilow reserve 
normalizes after bypass grafting (33.34), endothelium- 
dependent flow-mediated relaxation is impaired in venous as 
compared to arterial grafts (35). These functional differences, 
and the fact that the arterialization of venous grafts leads to 
profound fluid dynamic changes that increase the wall stress of 
the vessel (36). lead to early structural alterations (37) that 
further promote thrombosis in venous bypass vessels. 
These aspects of thrombogenic and therefore dynamic 
impairment of blood flow stress the relevance of antithrom- 
botic and thrombolytic eRcacy of long-term intermittent uroki- 
nase therapy as a major factor for the improvement of 
myocardial perfusion. The thrombolytic potential of different 
therapeutic regimens at low dose has been demon&rated 
(338,39). Furthermore two recent Uudies on the ad-ischemic 
efficacy of low molecular weight heparin (40,41) contributed to 
the concept of antithrombotic therapy as an anti-ischemic 
approach in stable angina ~0ri.s. Apart from the induction of 
collateral angiogenesis and functional improvement of cdl&- 
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crab (41-44). antithrombotic efficacy of low molecular weight 
heparin (29.40) is likely to bc of relevance. 
Asms of plaque regression for anti-ischemic elective- 
ness. It has been demonstrated that fibrinogen and fibrin are 
major constituents of atherosclerotic plaques (45-47) and 
high levels of fibrinogen are positively correlated with the 
extent of atheroma in the coronary and carotid arteries (48.49). 
This is regarded as a result of repetitive plaque rupture with 
formation of coronary thrombus, which, because of incomplete 
endogenous lysis, becomes incorporated into the plaque with 
subsequent rapid, nonlinear morphologic plaque progression 
(24). In addition, high fibrinogen levels in plasma lead to direct 
permeation of fibrinogen with an increased content of fibrin in 
the plaque (45). It is therefore probable that long-term throm- 
bolytic therapy may lead to actual morphologic plaque regres- 
sion, which is of particular relevance for blood flow in critically 
stenosed arteries. 
Potential pfothrombotii side effects of long-term iatermit- 
tent wokinase therapy. Investigations on thrombolysis in un- 
stable angina have demonstrated a cumulation of acute coro- 
nary ischemic events (50-52) in the treatment groups. which 
have been attributed to a variety of probable mechanisms such 
as increased thrombin generation (53-57), activation of plate- 
lets (58-60) and exposure of thrombogenic plaques (61). In 
contrast, it seems that mild thrombolytic therapy may have a 
favorable impact regarding these end points. Acute coronary 
events were reduced in group B, which received 3 X 500,CKlO IU 
urokinase, in comparison to the group that received the lower 
dosage (two patients vs. five patients). The low rate of acute 
ischemic events in the group that received 3 x 500,000 IU 
urokinase may be attributed to the daily oral administration of 
aspirin in all patients and the low dosage of urokinase used. It 
is at this point of interest to note that in patients with unstable 
angina, regimens with low dosages and prolonged infusiin of 
thrombolytic agents (62) may be superior to high dosages given 
over a short period. 
Limitations ol the study. A single-blinded study design was 
chosen for safety reasons. The absence of a placebo group is 
noteworthy because the inclusion of a true placebo group 
might have demonstrated even more signilicant effects for an 
application of 3 X 500.000 IU urokinase than did the compar- 
ison with the group that received 50,000 IU urokinase/ 
injection. In contrast, placebo effects on clinical efficacy are 
not completely ruled out by the study design chosen. 
The increase in exercise time to ST segment depression of 
0.1 mV in group B may seem small in relation to the marked 
reduction of spontaneous angina1 symptoms. Exercise testing 
was undertaken to assess maximal exercise capacity. but the 
record of spontaneous artginal symptoms does not necessarily 
reflect functional class. According to the data presented, 
functional exercise capacity increased by -60% in group B. In 
addition, results from exercise study I indicate that silent 
ischemia may have been a eottsiderabIe factor in group B. as 35 
patients reached negative ST segment &pres&n of 0. I mV on 
both occasions while the end point of augiaa peetoris was 
reduced from 32 to 14 after treatment. Repeated Holter 
recordings could hdve yielded valuable results on the interac- 
tion betw-en this form ot therapy and angina threshold, and 
hence coronary vasomotion and therapeutic effectiveness in 
respect to silent ischemia. 
ConclusIor~s. The anti-ixhemic and antianginal effective- 
ness of long-term intermittent urokinase therapy in addition to 
maximal conventional medical therapy implies that there do 
exist additional determinants of myocardial ischemia apart 
from the established therapeutic approaches that mainly influ- 
ence oxygen supply at the level of the epicardial coronary 
arteries or modify myocardial oxygen demand (63-66). This 
circumstance stresses the importance of factors that modulate 
coronary microcirculation and therefore myocardial perfusion, 
as has been emphasized previously for other diseases of the 
heart (6768). In addition, aspects of thrombogenesis in these 
highly symptomatic though clinically rather stable patients 
seem to be of particular relevance, as demonstrated by the 
efficacy of antithrombotic intervention. As these factors seem 
to be critical for myocardial perfusion under the given circum- 
stances. refractory angina pectoris in end-stage coronary artery 
disease may be regarded as a distinct coronary syndrome (69). 
We thank Sahine Meyer and Patricia TJia for help and assistance with manuscript 
preparation. 
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